Navigation Links
Ventral Hernia Repair Market to Grow to Over $800 Million in 2013
Date:10/14/2008

High adoption of xenograft mesh to drive revenues, according to Millennium

Research Group

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Soft Tissue Repair 2009 report, the US market for ventral hernia repair is valued at almost $500 million and is expected to rise to over $825 million over the next five years. This market comprises both synthetic mesh and biologic mesh materials, which can be sourced from humans (allograft) or animals (xenograft). High adoption of xenograft mesh, coupled with growth in the US elderly and obese populations, will help drive the ventral hernia repair market over the next five years.

A hernia occurs when a tissue, structure, or part of an organ protrudes through an abnormal opening in the body; it is most commonly associated with the projection of the intestine through a weakness in the abdominal wall. Those hernias that develop at the site of a previous surgical incision are called ventral hernias, and are the second most common type of hernia. The condition frequently occurs in the abdominal wall where a previous incision weakened the abdominal muscles, resulting in a bulging of the area. Ventral hernias present a challenge because they occur in a variety of sizes, may be quite complicated to repair, and have relatively high recurrence rates.

"Xenograft mesh will experience rapid adoption for complex hernia repair over the next five years," says David Plow, Manager of MRG's General Medical Technology division. "This mesh has shown to be stronger, less expensive, more widely available, and safer with respect to disease transmission when compared to allograft products."

MRG's global coverage of the soft tissue repair device market also includes data on Europe. US Markets for Soft Tissue Repair 2009 provides coverage of key industry competitors, including C.R. Bard, Cook Medical, Covidien, Ethicon, LifeCell, W.L. Gore, and more.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the health care sector. The company provides specialized industry expertise through published reports, ongoing Marketrack(TM) projects, and customized solutions.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the health care industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net

Elizabeth Marshall

Decision Resources Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
2. Stem cell regeneration repairs congenital heart defect
3. Neural Stem Cells May Help Repair Spina Bifida in Utero
4. Drug Given 24 Hours After Stroke Helps Repair Brain Tissue
5. Scripps research team unravels new cellular repair mechanism
6. New Skin Revitalizing Product Uses Naturally Occurring Serum for the Repair of Sun Damaged Skin
7. Spinal Cord Stem Cells May Act as Nerve Repair System
8. Faulty DNA repair could be a risk factor for lung cancer in nonsmokers
9. Evalve MitraClip: Clinical trial of nonsurgical repair for severe mitral valve regurgitation
10. 2nd Option Improves Abdominal Aorta Repair Outcomes
11. Joint distraction promotes structural repair in patients with severe knee osteoarthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist in ... cognitive decline. According to the research, which was published in the “Journal of the ... decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that dental ...
(Date:5/2/2016)... Boston, MA (PRWEB) , ... May 02, 2016 , ... ... and tips when trying to conceive. , “If you are ready to ... Dr. Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & ...
(Date:5/2/2016)... ... ... Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where he and ... Cities with the Highest Plastic Rates .” The other cities that made the list ... a survey by RealSelf and combining that data with the number of board-certified ...
(Date:5/2/2016)... Beach, FL (PRWEB) , ... May 02, 2016 , ... ... to great pain and suffering. With no cure, most patients must deal with prescription ... a free coupon card, allowing up to 75% savings at the pharmacy on many ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... which includes amniotic fluid/“stem cells” and Platelet Rich Plasma (PRP) injections. “These are ... said Dr. James Baranski, D.C., of Advanced Spine & Sport Medical. “We are ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... -- The blood testing market in China ... and The Freedonia Group in a recent report.  The ... healthcare research firm said that China ... and in improving testing at the provincial level.   The ... Blood Testing Market in China , which utilized ...
(Date:4/28/2016)... 2016   Acsis , a leading provider of ... market research and advisory firm IDC has named it ... Worldwide Pharmaceutical Track and Trace Software 2016 Vendor Assessment ... assessment of the capabilities and business strategies of 10 ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... 2016 Im ... Zürich gab Strekin AG den Start einer ... Erhaltung des Resthörvermögens von Patienten, denen ein ... umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan Patienten ... während der Operation direkt ins Mittelohr verabreicht. ...
Breaking Medicine Technology: